Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Radford

Showing results (31-40 of 110) with videos related to

Pageof 11
Sort By:
British Journal of Haematology|October 1, 2010
Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemiaAgathoclis Agathocleous, Ama Rohatiner, Simon Rule, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2021
Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin LymphomaDavid J Cutter, Johanna Ramroth, Patricia Diez, et al.
Blood Advances|January 8, 2025
Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international studyElizabeth H Phillips, Nicholas Counsell, Tim Illidge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2013
De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trialPaul A Fields, William Townsend, Andrew Webb, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2023
Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma TrialStefano Luminari, Alexander Fossa, Judith Trotman, et al.
Blood Advances|September 3, 2021
Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trialAlex F Herrera, Catherine Burton, John Radford, et al.
JMIR Research Protocols|September 8, 2019
Exploring Severe Mental Illness and Diabetes: Protocol for a Longitudinal, Observational, and Qualitative Mixed Methods StudySue Bellass, Johanna Taylor, Lu Han, et al.
F1000Research|October 23, 2020
ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trialAndrew Davies, Sharon Barrans, Cathy Burton, et al.
The Oncologist|October 10, 2013
A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphomaAndré Bosly, Andrew Grigg, Harald Holte, et al.
British Journal of Haematology|December 21, 2022
Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trialsValeria Fiaccadori, Anouk Neven, Catherine Fortpied, et al.
Pageof 11

Showing results (31-40 of 110) with videos related to

Sort By:
Pageof 11
British Journal of Haematology|October 1, 2010
Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemiaAgathoclis Agathocleous, Ama Rohatiner, Simon Rule, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2021
Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin LymphomaDavid J Cutter, Johanna Ramroth, Patricia Diez, et al.
Blood Advances|January 8, 2025
Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international studyElizabeth H Phillips, Nicholas Counsell, Tim Illidge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2013
De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trialPaul A Fields, William Townsend, Andrew Webb, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2023
Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma TrialStefano Luminari, Alexander Fossa, Judith Trotman, et al.
Blood Advances|September 3, 2021
Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trialAlex F Herrera, Catherine Burton, John Radford, et al.
JMIR Research Protocols|September 8, 2019
Exploring Severe Mental Illness and Diabetes: Protocol for a Longitudinal, Observational, and Qualitative Mixed Methods StudySue Bellass, Johanna Taylor, Lu Han, et al.
F1000Research|October 23, 2020
ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trialAndrew Davies, Sharon Barrans, Cathy Burton, et al.
The Oncologist|October 10, 2013
A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphomaAndré Bosly, Andrew Grigg, Harald Holte, et al.
British Journal of Haematology|December 21, 2022
Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trialsValeria Fiaccadori, Anouk Neven, Catherine Fortpied, et al.
Pageof 11